We pioneer the frontiers of medical treatments with programmable medicines.

At CPTx, our mission is to transform healthcare with innovative solutions for formidable medical challenges.

Our multidisciplinary team of experts has come together to create a breakthrough platform that harnesses the power of programmable DNA nanofabrication and AI-supported molecular design, ensuring safety, efficacy, and versatility.

image of cptx team working

Our Story

CPTx was founded in 2021 with the aim of leveraging DNA-based nanofabrication to provide solutions for unsolved medical needs.

CPTx stems from more than 15 years of research at the Technical University of Munich. We build on inventions and major scientific discoveries published in renowned journals such as Nature and Science. More than 90 research papers have been authored by CPTx innovators and multiple patents have been registered.

The company is led by founder CEO Hendrik Dietz, a physicist and pioneer of DNA nanotechnology who has been awarded with numerous distinctions including the Leibniz Prize, the highest scientific distinction in Germany. The leadership team combines both academic and industry experts, experienced in leading some of the world's most successful biotech firms from inception to IPO and exit.

  • 15

    Total Years of Research
  • 10

    Nature and Science Papers
  • 80

    Research Papers
Meet Our Team

Leadership Team

Hendrik Dietz, PhD

ceo & founder

Forgoing a career as a pilot, Hendrik decided to pursue his passion for science at the Technical University of Munich and then at Harvard Medical School and the Dana-Farber Cancer Institute.

While gaining tenure as a full professor at TUM, he focused exclusively on advancing programmable DNA nanofabrication for over 15 years. Committed to transforming theoretical ideas into practical applications, Hendrik founded and leads CPTx, a company that aims to revolutionize medicine with bionanotechnology.

portrait of hendrik dietz
portrait of grant boldt

Grant Boldt, PhD


Grant Boldt, our chief operations officer, holds a Ph.D. in Chemical Biology from Scripps Research Institute, fueling his fast-paced career in the biopharma industry.

With senior executive roles as Vice President and P&L owner at biotechs including Sigma Aldrich, Lonza, and Avantor, Grant has driven fast business growth and shaped the trajectory of global corporations.

His motto is difficilia quae pulchra - in difficulty lies beauty. Grant has a passion for complexity and his adventurous spirit finds motorcycle racing and company building equally compelling.

Christian Sigl, PhD

CTO & Founder

Meet Christian Sigl: the trailblazing CTO of CPTx and former volunteer firefighter turned DNA nanoengineer. His love for geometric patterns like icosahedrons and pentagons is at the heart of his innovative approach to biotech. Christian's groundbreaking doctoral work was crucial in developing CPTx’s first therapeutic breakthrough—the antiviral nanochassis.

At CPTx, Christian combines his blend of emergency management skills and biophysical insight to lead pioneering technological advancements for precision-based therapies.

portrait of christian sigl
portrait of stefan oschmann

Stefan Oschmann, PhD

chairman of the board

Stefan is a seasoned executive with extensive experience in biopharma, life science tools, and specialty chemicals. He was the Chairman and CEO at Merck KGaA, where he spearheaded the company's successful transformation into a leading science and technology firm. Under his leadership, Merck introduced two blockbuster products in neuroscience and oncology.

Following his seven-year tenure at Merck, Stefan became chairman of UCB and AiCuris, and he currently works as a partner at the private equity firm Armira. His earlier career included senior roles at Merck & Co. (MSD), including President of Emerging Markets and President of Europe/Middle East/Africa, after starting in R&D at MSD and working in research at the International Atomic Energy Agency. Stefan earned a doctorate (DVM) from the University of Munich.

Our Production Facility

Our state-of-the-art production facility is at the forefront of nanofabrication technology. Designed with precision, our facility boasts both upstream and downstream processing capabilities for the mass production of programmable therapeutics.

We are committed to excellence and safety, and are currently upgrading our operations to meet Good Manufacturing Practice (GMP) standards.

3,600 m2
In-house manufacturing and process development facility
image of cptx facility

Supported By

logo of sprin-dlogo of blueyard